Affinium Pharmaceuticals

Skip to content

Main Navigation:

TARGETED ANTIBIOTICS FOR SERIOUS INFECTIONS

Affinium is a specialty pharmaceutical company developing a novel class of antibiotics that target the bacterial fatty acid synthesis pathway. AFN-1252, our lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.

MARCH 20, 2013

Affinium Pharmaceuticals Announces Positive Efficacy, Safety, and Tolerability Results from Phase 2a Clinical Trial of Oral AFN-1252 in Acute Bacterial Skin & Skin Structure Infections Click for PDF version (PDF 245KB)

MARCH 13, 2013

Affinium Pharmaceuticals, Ltd., Announces the Appointments of Ed Mascioli, MD to the Position of Chief Executive Officer and Robert Radie to the Board of Directors Click for PDF version (PDF 48KB)

AUGUST 7, 2012

Affinium Pharmaceuticals, Ltd., A nnounces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections Click for PDF version (PDF 28KB)

FEBRUARY 1, 2012

Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed with Oral AFN-1252 in a Phase 2 Clinical Trial for Acute Bacterial Skin & Skin Structure Infections Click for PDF version (PDF 29KB)

Tab1
Tab2
Tab3
Tab4

You can meet us at:

BIO Annual Meeting, April 21-24, 2013. Chicago, IL
23rd ECCMID, April 27-30, 2013. Berlin, Germany